TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

TGA presentation given at Parenteral Drug Association Australia Chapter meeting, 24 November 2015

Manufacturing Quality Branch - 2015 achievements and challenges

6 December 2015

Disclaimer

These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.

The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.

Presentation

  • Presented by: Harry Rothenfluh, Assistant Secretary, Manufacturing Quality Branch, Therapeutic Goods Administration
  • Presented at: PDA Australia Chapter Meeting, 24 November 2015
  • Presentation summary: This presentation provided an update on the achievements and challenges for MQB in 2015

Transcript

Manufacturing Quality Branch – 2015 Achievements and Challenges

Harry Rothenfluh, PhD
Assistant Secretary
Manufacturing Quality Branch

PDA Australia Chapter Meeting, 24 November 2015

Slide 1 - Overview

  • 2015: Achievements and challenges
    • GMP clearances
    • Inspections performance data
  • Looking ahead to 2016
    • Inspection close out process improvement
    • Rewarding consistent high levels of compliance

Slide 2 - GMP clearances

Slide 3 - GMP clearance applications

clearance applications table

Slide 4 - What are we doing to reduce clearance times?

Improving our ability to meet demand

  • OMQ restructure: aligning structure with function
  • Improved application triaging
  • Improved information management

Communication

  • Updates on TGA website
  • PDA presentations!
  • TGA - Industry Working Group on Manufacturing Quality

Slide 5 - GMP clearance processing times - median

table weeks to completion

Slide 6 - GMP clearance processing times - average

table clearance processing times

Slide 7 - Inspections

Slide 8 - What's in store for 2016?

Helping sponsors understand their role

  • GMP clearance application tool
  • GMP clearance guideline revision

Reducing impact of poor quality applications

  • Decisions will be made based on information provided by the sponsor in the application

Slide 9 - Inspection performance

2014-15

  • 92% of domestic initial inspections conducted within target timelines (3 months)

2015-16 to end October

  • 94% of domestic reinspections (44/47) conducted within target timelines (6 months)

Slide 10 - What's in store for 2016?

Revised inspection close out process

  • Objective:
    • Predictable inspection close out times for manufacturers who comply with requirements
  • How:
    • No objective evidence required if acceptable CAPAs
    • Next inspection will include assessment of CAPAs
    • Limited rounds of additional information requests

Slide 11 - What's in store for 2016?

Rewarding consistent high levels of compliance.

  • Objective:
    • Reduced regulatory burden for manufacturers with repeat A1 rating
  • How:
    • 3 year reinspection frequency for A1 manufacturers of high risk products (currently 2 years)
    • Second and subsequent A1 ratings: reduced scope inspection

Slide 12 - Questions?

Print version

How to access a pdf document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.